title: Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid.
abstract: OBJECTIVE
  To assess the effectiveness and safety of fingolimod use in a Spanish clinical practice setting.
  
  
  METHODS
  Retrospective study with multiple sclerosis patients who received at least 1 fingolimod dose between January 2004 and January 2015. Effectiveness and safety data were collected during the entire treatment of each patient. Analysis was performed for the total population and stratified according to prior treatment, sex, and age at treatment initiation.
  
  
  RESULTS
  A total of 167 patients were included, 50.9% had prior immunomodulator use, 33.5% natalizumab use, and 15.6% were naive patients. The annual relapse rate (ARR) decreased for the total population at month 12 (62%) and month 24 (84%) (P < 0.0001, in both cases); for naive patients (P < 0.05) and patients with prior immunomodulator use (P < 0.0001); for patients with prior natalizumab use, the ARR kept low after treatment initiation (0.23). After 24 months, the proportion of relapse-free patients was 70% or greater and disability progression-free patients was 80% or greater. No significant differences were observed when the results were compared by prior treatment, sex, or age. Thirty-two patients (19.2%) reported adverse drug reactions and 9.6% discontinued: 4.8% due to adverse drug reactions and 4.8% for lack of effectiveness.
  
  
  CONCLUSIONS
  The results support fingolimod use due to clinical effectiveness, tolerability, and ease of administration.
authors.affiliation: *Hospital Universitario Príncipe de Asturias, Servicio de Neurología, Alcalá de Henares; †Hospital Universitario de Torrejón, Servicio de Neurología, Torrejón de Ardoz; ‡Instituto de Investigación Sanitaria del Hopsital Clínico San Carlos (IdISSC); and §Hospital Universitario Quirón Madrid, Servicio de Neurología, Madrid, Spain.
authors.forename: Victoria
authors.initials: V
authors.lastname: Galán Sánchez-Seco
authors.forename: Ignacio
authors.initials: I
authors.lastname: Casanova-Peño
authors.forename: Roberto
authors.initials: R
authors.lastname: Álvarez-Lafuente
authors.forename: Mónica
authors.initials: M
authors.lastname: Sánchez-Jiménez
authors.forename: Ángel
authors.initials: Á
authors.lastname: García-Martínez
authors.forename: María Inmaculada
authors.initials: MI
authors.lastname: Domínguez-Mozo
authors.forename: Ana María
authors.initials: AM
authors.lastname: Arias-Leal
authors.forename: Marta
authors.initials: M
authors.lastname: García-Montojo
authors.forename: Rafael
authors.initials: R
authors.lastname: Arroyo-González
mesh_terms: D000328:Adult; D004185:Disability Evaluation; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012008:Recurrence; D012189:Retrospective Studies; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride